In HCC tumors formed by MHCC97-L cells or HepG2, overexpression of TPX2 led to the acceleration of the metabolism or clearance of sorafenib (Fig. 5B, F), and the t1/2 value of sorafenib decreased (Table 7). Here, TPX2 is linked to hepatocellular carcinoma.